{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:33:47Z","timestamp":1788240827688,"version":"build-2803163510"},"reference-count":80,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in 2014 when eltrombopag, a thrombopoietin receptor agonist, was approved for SAA after an insufficient response to initial immunosuppressive therapy (IST). The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% recovered blood counts at times involving &gt;1 lineage. The achievement of transfusion independence confirmed the clinical benefit of this approach. Increase in marrow cellularity and CD34+ cells suggested a recovery to a more functioning bone marrow. Further in its development, eltrombopag was associated with standard horse ATG plus cyclosporine in first line, producing increases in overall (at about 90%) and complete response rates (at about 40%) and leading to transfusion independence and excellent survival. Interestingly, best results were observed when all drugs were started simultaneously. The cumulative incidence of clonal cytogenetic abnormalities to date has compared favorably with the vast experience with IST alone in SAA. Longer follow-up will help in define these long-term risks. In this review, the development of eltrombopag in SAA will be discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.450","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Activity of eltrombopag in severe aplastic anemia"],"prefix":"10.1182","volume":"2018","author":[{"given":"Phillip","family":"Scheinberg","sequence":"first","affiliation":[{"name":"Division of Hematology, Hospital A Benefic\u00eancia Portuguesa, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111521353937700_B1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111521353937700_B2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2002-04-1134","article-title":"Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia","volume":"101","author":"Frickhofen","year":"2003","journal-title":"Blood"},{"issue":"19","key":"2019111521353937700_B3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJM199105093241901","article-title":"Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine","volume":"324","author":"Frickhofen","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111521353937700_B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1989.tb00230.x","article-title":"Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin","volume":"73","author":"de Planque","year":"1989","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111521353937700_B5","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","article-title":"Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome","volume":"289","author":"Rosenfeld","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"2019111521353937700_B6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.13829","article-title":"Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study","volume":"94","author":"Scheinberg","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2019111521353937700_B7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2006.06085.x","article-title":"Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil","volume":"133","author":"Scheinberg","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111521353937700_B8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.23692","article-title":"Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia","volume":"89","author":"Scheinberg","year":"2014","journal-title":"Am J Hematol"},{"issue":"18","key":"2019111521353937700_B9","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1182\/blood-2014-05-573642","article-title":"Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution","volume":"124","author":"Scheinberg","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111521353937700_B10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111521353937700_B11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"9241","key":"2019111521353937700_B12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0140-6736(00)03126-3","article-title":"High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial","volume":"356","author":"Tisdale","year":"2000","journal-title":"Lancet"},{"issue":"23","key":"2019111521353937700_B13","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2012-02-407684","article-title":"Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party [published correction appears in Blood. 2013;121(25):5104]","volume":"119","author":"Marsh","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111521353937700_B14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.exphem.2006.03.017","article-title":"Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens","volume":"34","author":"Zheng","year":"2006","journal-title":"Exp Hematol"},{"issue":"13","key":"2019111521353937700_B15","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1182\/blood-2002-02-0494","article-title":"Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial","volume":"100","author":"Tisdale","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111521353937700_B16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.1999.01693.x","article-title":"Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO) [published correction appears in Br J Haematol. 2000;108(2):461]","volume":"107","author":"Di Bona","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111521353937700_B17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2006.06098.x","article-title":"Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia","volume":"133","author":"Scheinberg","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111521353937700_B18","first-page":"264","article-title":"Comparison of two dosages of rabbit antithymocyte globulin (r-ATG) in treating children with severe aplastic anemia","volume":"73","author":"Lin","year":"2018","journal-title":"Pharmazie"},{"key":"2019111521353937700_B19","article-title":"Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study [published online ahead of print 5 July 2018]","author":"Cl\u00e9","journal-title":"Ann Hematol"},{"issue":"3","key":"2019111521353937700_B20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2008.002329","article-title":"Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?","volume":"94","author":"Passweg","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2019111521353937700_B21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-017-2179-3","article-title":"Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia","volume":"105","author":"Hayakawa","year":"2017","journal-title":"Int J Hematol"},{"issue":"11","key":"2019111521353937700_B22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMc1607752","article-title":"Danazol treatment for telomere diseases","volume":"375","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111521353937700_B23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.seminhematol.2007.04.010","article-title":"Hematopoietic growth factors in the treatment of acquired bone marrow failure states","volume":"44","author":"Marsh","year":"2007","journal-title":"Semin Hematol"},{"issue":"1","key":"2019111521353937700_B24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0037-1963(00)90032-5","article-title":"Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia","volume":"37","author":"Marsh","year":"2000","journal-title":"Semin Hematol"},{"issue":"8","key":"2019111521353937700_B25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3109\/10428194.2011.568646","article-title":"Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches","volume":"52","author":"F\u00fcreder","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111521353937700_B26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111521353937700_B27","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111521353937700_B28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(94)01008-0","article-title":"Molecular cloning and chromosomal localization of the human thrombopoietin gene","volume":"353","author":"Sohma","year":"1994","journal-title":"FEBS Lett"},{"issue":"7","key":"2019111521353937700_B29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"issue":"6481","key":"2019111521353937700_B30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature"},{"issue":"6","key":"2019111521353937700_B31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"6","key":"2019111521353937700_B32","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162","article-title":"Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl","volume":"87","author":"Alexander","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2019111521353937700_B33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","article-title":"Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells","volume":"1","author":"Qian","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2019111521353937700_B34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI0215430","article-title":"Thrombopoietin expands hematopoietic stem cells after transplantation","volume":"110","author":"Fox","year":"2002","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111521353937700_B35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.V92.1.4.413k38_4_10","article-title":"Role of c-mpl in early hematopoiesis","volume":"92","author":"Solar","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2019111521353937700_B36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2003.tb03228.x","article-title":"Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia","volume":"996","author":"Ballmaier","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2019111521353937700_B37","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1073\/pnas.96.6.3132","article-title":"Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia","volume":"96","author":"Ihara","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111521353937700_B38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004390000357","article-title":"Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT)","volume":"107","author":"Tonelli","year":"2000","journal-title":"Hum Genet"},{"issue":"1","key":"2019111521353937700_B39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V97.1.139","article-title":"c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia","volume":"97","author":"Ballmaier","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111521353937700_B40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111521353937700_B41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3324\/haematol.2010.030536","article-title":"Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes","volume":"96","author":"Feng","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111521353937700_B42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111521353937700_B43","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111521353937700_B44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.V130.Suppl_1.777.777","article-title":"Eltrombopag for refractory severe aplastic anemia: dosing regimens, long-term follow-up, clonal evolution and somatic mutation profiling [abstract]","volume":"130","author":"Winkler","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111521353937700_B45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111521353937700_B46","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2017-07-794362","article-title":"Clonality in context: hematopoietic clones in their marrow environment","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2019111521353937700_B47","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111521353937700_B48","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111521353937700_B49","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"17","key":"2019111521353937700_B50","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111521353937700_B51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hoc.2018.03.003","article-title":"Recent advances and long-term results of medical treatment of acquired aplastic anemia: are patients cured?","volume":"32","author":"Scheinberg","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2019111521353937700_B52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111521353937700_B53","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1038\/s41598-017-08699-z","article-title":"Expression of CXCR4 on T-cell subsets and plasma IL-17 concentrations in patients with aplastic anaemia","volume":"7","author":"Niu","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"2019111521353937700_B54","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/blood-2014-08-594796","article-title":"CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia","volume":"125","author":"Arieta Kuksin","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111521353937700_B55","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2011-11-390708","article-title":"Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111521353937700_B56","doi-asserted-by":"crossref","first-page":"e26764","DOI":"10.4161\/rdis.26764","article-title":"NOTCH signaling in immune-mediated bone marrow failure of aplastic anemia","volume":"1","author":"Minter","year":"2013","journal-title":"Rare Dis"},{"issue":"1","key":"2019111521353937700_B57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2007.06627.x","article-title":"Decreased TCR zeta-chain expression in T cells from patients with acquired aplastic anaemia","volume":"138","author":"Solomou","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111521353937700_B58","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood-2007-01-066258","article-title":"Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia","volume":"110","author":"Solomou","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111521353937700_B59","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood-2005-10-4201","article-title":"T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia","volume":"107","author":"Solomou","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2019111521353937700_B60","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2010-01-266098","article-title":"Th17 immune responses contribute to the pathophysiology of aplastic anemia","volume":"116","author":"de Latour","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111521353937700_B61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminhematol.2013.03.028","article-title":"Aplastic anemia: what have we learned from animal models and from the clinic","volume":"50","author":"Scheinberg","year":"2013","journal-title":"Semin Hematol"},{"issue":"9431","key":"2019111521353937700_B62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(04)16724-X","article-title":"In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing","volume":"364","author":"Risitano","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"2019111521353937700_B63","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2016-03-703702","article-title":"Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment","volume":"128","author":"Kordasti","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111521353937700_B64","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111521353937700_B65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-014-1661-4","article-title":"Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia","volume":"100","author":"Nishimoto","year":"2014","journal-title":"Int J Hematol"},{"issue":"suppl 1","key":"2019111521353937700_B66","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"Schifferli","year":"2016","journal-title":"Semin Hematol"},{"issue":"6","key":"2019111521353937700_B67","first-page":"1219","article-title":"Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells","volume":"112","author":"Sadallah","year":"2014","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111521353937700_B68","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.4049\/jimmunol.1002788","article-title":"Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells","volume":"186","author":"Sadallah","year":"2011","journal-title":"J Immunol"},{"issue":"suppl 1","key":"2019111521353937700_B69","first-page":"4","article-title":"Heterodimerization of TPO and IFN\u03b3 impairs human hematopoietic stem\/progenitor cell signaling and survival in chronic inflammation [abstract]","volume":"130","author":"Alvarado","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2019111521353937700_B70","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111521353937700_B71","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.24705","article-title":"Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia","volume":"92","author":"Lambert","year":"2017","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111521353937700_B72","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2018-01-826784","article-title":"Eltrombopag mobilizes iron in patients with aplastic anemia","volume":"131","author":"Zhao","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019111521353937700_B73","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bjh.13151","article-title":"The oral iron chelator deferasirox inhibits NF-\u03baB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia","volume":"168","author":"Banerjee","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111521353937700_B74","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/trf.12507","article-title":"Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia","volume":"54","author":"Cheong","year":"2014","journal-title":"Transfusion"},{"issue":"2","key":"2019111521353937700_B75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000342772","article-title":"Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia","volume":"129","author":"Lee","year":"2013","journal-title":"Acta Haematol"},{"issue":"7","key":"2019111521353937700_B76","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2012.077669","article-title":"Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study","volume":"98","author":"Lee","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111521353937700_B77","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bjh.14024","article-title":"The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia","volume":"176","author":"Gill","year":"2017","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111521353937700_B78","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood.V128.22.3910.3910","article-title":"Efficacy and safety of romiplostim in patients with aplastic anemia refractory to immunosuppressive therapy: 1-year interim analysis of phase 2 clinical trial","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111521353937700_B79","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3324\/haematol.2017.176339","article-title":"Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia","volume":"103","author":"Lengline","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2019111521353937700_B80","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10245332.2017.1422306","article-title":"Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting","volume":"23","author":"Hwang","year":"2018","journal-title":"Hematology"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/450\/1252851\/hem01862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/450\/1252851\/hem01862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:15:19Z","timestamp":1663298119000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/450\/277581\/Activity-of-eltrombopag-in-severe-aplastic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.450","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}